This award is a consequence of the nucleoside patents owned by Idenix, which was acquired by MRK for $3.85B in 2014 (#msg-103051902). So, while MRK did not derive much benefit clinically from the IDIX deal (#msg-126517784), they did recapture a lot of the purchase price.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.